Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 5Gastrointestinal 4Thoracic 3Breast 3Other hematologic neoplasm 2Tumor-Agnostic 1Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mass Screening × Head & Neck × 1 year × Clear all
NCT04965792 2025-06-17

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Dana-Farber Cancer Institute

Active not recruiting
150 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡